CYTK logo

CYTK
Cytokinetics Inc

4,587
Mkt Cap
$9.57B
Volume
5.79M
52W High
$80.20
52W Low
$29.31
PE Ratio
-11.24
CYTK Fundamentals
Price
$76.91
Prev Close
$74.29
Open
$74.51
50D MA
$64.49
Beta
0.91
Avg. Volume
1.66M
EPS (Annual)
-$6.54
P/B
-11.56
Rev/Employee
$130,815.75
$8,030.25
Loading...
Loading...
News
all
press releases
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch
Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.
Zacks·3d ago
News Placeholder
More News
News Placeholder
Cytokinetics (NASDAQ:CYTK) Posts Quarterly Earnings Results
Cytokinetics (NASDAQ:CYTK - Get Free Report) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.67) EPS for the quarter, hitting analysts' consensus estimates of ($1.67). The business had revenue of $19.36 million for the quarter, compared to analyst...
MarketBeat·4d ago
News Placeholder
Cytokinetics Q1 Earnings Call Highlights
Cytokinetics (NASDAQ:CYTK) highlighted the first full quarter as a commercial-stage company during its first-quarter 2026 earnings call, pointing to early U.S. demand for its newly launched...
MarketBeat·4d ago
News Placeholder
Cytokinetics (NASDAQ:CYTK) EVP Sells $270,795.00 in Stock
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 3,500 shares of Cytokinetics stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $77.37, for a total value of $270,795.00. Following the sale, the executive vice president...
MarketBeat·4d ago
News Placeholder
Cytokinetics Shares Phase 3 ACACIA-HCM Win: Aficamten Hits Dual Endpoints in nHCM Trial
Cytokinetics (NASDAQ:CYTK) reported positive top-line results from ACACIA-HCM, a pivotal Phase 3 trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy...
MarketBeat·4d ago
News Placeholder
Cytokinetics (CYTK) Reports Q1 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of -0.20% and +173.34%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Cytokinetics (CYTK) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·4d ago
News Placeholder
Needham & Company LLC Issues Positive Forecast for Cytokinetics (NASDAQ:CYTK) Stock Price
Needham & Company LLC lifted their price target on Cytokinetics from $85.00 to $102.00 and gave the company a "buy" rating in a research report on Tuesday...
MarketBeat·4d ago
News Placeholder
Mid Cap Stocks To Research - May 5th
Arcellx, ProShares UltraPro Short QQQ, Cytokinetics, Cipher Mining, Direxion Daily MU Bull 2X Shares, Direxion Daily TSLA Bull 2X Shares, and AXT are the seven Mid Cap stocks to watch today...
MarketBeat·4d ago
News Placeholder
Top Pharmaceutical Stocks To Research - May 5th
Eli Lilly and Company, Cytokinetics, Pfizer, Abbott Laboratories, and Vertex Pharmaceuticals are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, or distri...
MarketBeat·4d ago
<
1
2
...
>

Latest CYTK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.